-
1
-
-
77955273537
-
-
In: IARC Cancer Base No 10. Lyon, France: International Agency for Research on Cancer; 2010. Available from:, Accessed December 14, 2012
-
Ferlay J, Shin HR, Bray F, et al. Cancer incidence and mortality worldwide. In: IARC Cancer Base No 10. Lyon, France: International Agency for Research on Cancer; 2010. Available from: http://globocan.iarc.fr. Accessed December 14, 2012.
-
Cancer incidence and mortality worldwide
-
-
Ferlay, J.1
Shin, H.R.2
Bray, F.3
-
2
-
-
67650874081
-
Cancer statistics, 2009
-
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59(4):225-249.
-
(2009)
CA Cancer J Clin
, vol.59
, Issue.4
, pp. 225-249
-
-
Jemal, A.1
Siegel, R.2
Ward, E.3
Hao, Y.4
Xu, J.5
Thun, M.J.6
-
3
-
-
33846245932
-
Development of an ovarian cancer symptom index: Possibilities for earlier detection
-
Goff BA, Mandel LS, Drescher CW, et al. Development of an ovarian cancer symptom index: possibilities for earlier detection. Cancer. 2007;109(2):221-227.
-
(2007)
Cancer
, vol.109
, Issue.2
, pp. 221-227
-
-
Goff, B.A.1
Mandel, L.S.2
Drescher, C.W.3
-
4
-
-
84856237897
-
Identifying women with suspected ovarian cancer in primary care: Derivation and validation of algorithm
-
Hippisley-Cox J, Coupland C. Identifying women with suspected ovarian cancer in primary care: derivation and validation of algorithm. BMJ. 2011;344:d8009.
-
(2011)
BMJ
, vol.344
-
-
Hippisley-Cox, J.1
Coupland, C.2
-
5
-
-
79958036419
-
Effect of screening on ovarian cancer mortality: The Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening randomized controlled trial
-
Buys SS, Partridge E, Black A, et al. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening randomized controlled trial. JAMA. 2011;305(22):2295-2303.
-
(2011)
JAMA
, vol.305
, Issue.22
, pp. 2295-2303
-
-
Buys, S.S.1
Partridge, E.2
Black, A.3
-
6
-
-
84863677050
-
The UKCTOCS experience-reasons for hope?
-
Menon U, Kalsi J, Jacobs I. The UKCTOCS experience-reasons for hope? Int J Gynecol Cancer. 2012;22 Suppl 1:S18-S20.
-
(2012)
Int J Gynecol Cancer
, vol.22
, Issue.SUPPL. 1
-
-
Menon, U.1
Kalsi, J.2
Jacobs, I.3
-
7
-
-
0030054309
-
Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer
-
McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996;334(1):1-6.
-
(1996)
N Engl J Med
, vol.334
, Issue.1
, pp. 1-6
-
-
McGuire, W.P.1
Hoskins, W.J.2
Brady, M.F.3
-
8
-
-
0034600305
-
Randomized Intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: Three-year results
-
Piccart MJ, Bertelsen K, James K, et al. Randomized Intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst. 2000;92(9):699-708.
-
(2000)
J Natl Cancer Inst
, vol.92
, Issue.9
, pp. 699-708
-
-
Piccart, M.J.1
Bertelsen, K.2
James, K.3
-
9
-
-
0032960938
-
First line chemotherapy with carboplatin plus paclitaxel in advanced ovarian cancer-a new standard of care?
-
du Bois A, Neijt JP, Thigpen JT. First line chemotherapy with carboplatin plus paclitaxel in advanced ovarian cancer-a new standard of care? Ann Oncol. 1999;10 Suppl 1:35-41.
-
(1999)
Ann Oncol
, vol.10
, Issue.SUPPL. 1
, pp. 35-41
-
-
du Bois, A.1
Neijt, J.P.2
Thigpen, J.T.3
-
10
-
-
9744223515
-
Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma
-
Vasey PA, Jayson GC, Gordon A, et al. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst. 2004;96(22):1682-1691.
-
(2004)
J Natl Cancer Inst
, vol.96
, Issue.22
, pp. 1682-1691
-
-
Vasey, P.A.1
Jayson, G.C.2
Gordon, A.3
-
11
-
-
0037125582
-
Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: The ICON3 randomised trial
-
International Collaborative Ovarian Neoplasm Group
-
International Collaborative Ovarian Neoplasm Group. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet. 2002;360(9332):505-515.
-
(2002)
Lancet
, vol.360
, Issue.9332
, pp. 505-515
-
-
-
12
-
-
0033986363
-
Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: A Gynecologic Oncology Group study
-
Muggia FM, Braly PS, Brady MF, et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2000;18(1):106-115.
-
(2000)
J Clin Oncol
, vol.18
, Issue.1
, pp. 106-115
-
-
Muggia, F.M.1
Braly, P.S.2
Brady, M.F.3
-
13
-
-
27744551640
-
2004 consensus statements on the management of ovarian cancer: Final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004)
-
du Bois A, Quinn M, Thigpen T, et al. 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann Oncol. 2005;16 Suppl 8:viii7-viii12.
-
(2005)
Ann Oncol
, vol.16
, Issue.SUPPL. 8
-
-
du Bois, A.1
Quinn, M.2
Thigpen, T.3
-
14
-
-
63049115790
-
Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: A Phase III trial of the Gynecologic Cancer Intergroup
-
Bookman MA, Brady MF, McGuire WP, et al. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III trial of the Gynecologic Cancer Intergroup. J Clin Oncol. 2009;27(9):1419-1425.
-
(2009)
J Clin Oncol
, vol.27
, Issue.9
, pp. 1419-1425
-
-
Bookman, M.A.1
Brady, M.F.2
McGuire, W.P.3
-
15
-
-
0028952438
-
The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer
-
van der Burg ME, van Lent M, Buyse M, et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med. 1995;332(10):629-634.
-
(1995)
N Engl J Med
, vol.332
, Issue.10
, pp. 629-634
-
-
van der Burg, M.E.1
van Lent, M.2
Buyse, M.3
-
16
-
-
77956640361
-
Neoadjuvant chemotherapy in advanced ovarian cancer: What kind of evidence is needed to convince US gynaecological oncologists?
-
Vergote I, Amant F, Leunen K. Neoadjuvant chemotherapy in advanced ovarian cancer: what kind of evidence is needed to convince US gynaecological oncologists? Gynecol Oncol. 2010;119(1):1-2.
-
(2010)
Gynecol Oncol
, vol.119
, Issue.1
, pp. 1-2
-
-
Vergote, I.1
Amant, F.2
Leunen, K.3
-
17
-
-
39049102018
-
Phase III trial of upfront debulking surgery versus neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers: Japan Clinical Oncology Group Study JCOG0602
-
Onda T, Matsumoto K, Shibata T, et al. Phase III trial of upfront debulking surgery versus neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers: Japan Clinical Oncology Group Study JCOG0602. Jpn J Clin Oncol. 2008;38(1):74-77.
-
(2008)
Jpn J Clin Oncol
, vol.38
, Issue.1
, pp. 74-77
-
-
Onda, T.1
Matsumoto, K.2
Shibata, T.3
-
18
-
-
80755167871
-
Neoadjuvant chemotherapy is the better treatment option in some patients with stage IIIc to IV ovarian cancer
-
Vergote I, Trope CG, Amant F, Ehlen T, Reed NS, Casado A. Neoadjuvant chemotherapy is the better treatment option in some patients with stage IIIc to IV ovarian cancer. J Clin Oncol. 2011;29(31):4076-4078.
-
(2011)
J Clin Oncol
, vol.29
, Issue.31
, pp. 4076-4078
-
-
Vergote, I.1
Trope, C.G.2
Amant, F.3
Ehlen, T.4
Reed, N.S.5
Casado, A.6
-
19
-
-
84862302151
-
Primary debulking surgery versus neoadjuvant chemotherapy in stage IV ovarian cancer
-
Rauh-Hain JA, Rodriguez N, Growdon WB, et al. Primary debulking surgery versus neoadjuvant chemotherapy in stage IV ovarian cancer. Ann Surg Oncol. 2012;19(3):959-965.
-
(2012)
Ann Surg Oncol
, vol.19
, Issue.3
, pp. 959-965
-
-
Rauh-Hain, J.A.1
Rodriguez, N.2
Growdon, W.B.3
-
20
-
-
0035865144
-
Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: An intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group
-
Markman M, Bundy BN, Alberts DS, et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol. 2001;19(4):1001-1007.
-
(2001)
J Clin Oncol
, vol.19
, Issue.4
, pp. 1001-1007
-
-
Markman, M.1
Bundy, B.N.2
Alberts, D.S.3
-
21
-
-
30044438368
-
Intraperitoneal cisplatin and paclitaxel in ovarian cancer
-
Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354(1):34-43.
-
(2006)
N Engl J Med
, vol.354
, Issue.1
, pp. 34-43
-
-
Armstrong, D.K.1
Bundy, B.2
Wenzel, L.3
-
22
-
-
43249115659
-
Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: Final results of Cancer and Leukemia Group B protocol 9840
-
Seidman AD, Berry D, Cirrincione C, et al. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol. 2008;26(10):1642-1649.
-
(2008)
J Clin Oncol
, vol.26
, Issue.10
, pp. 1642-1649
-
-
Seidman, A.D.1
Berry, D.2
Cirrincione, C.3
-
23
-
-
42249083269
-
Weekly paclitaxel in the adjuvant treatment of breast cancer
-
Sparano JA, Wang M, Martino S, et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med. 2008;358(16):1663-1671.
-
(2008)
N Engl J Med
, vol.358
, Issue.16
, pp. 1663-1671
-
-
Sparano, J.A.1
Wang, M.2
Martino, S.3
-
24
-
-
70349878651
-
Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: A phase 3, open-label, randomised controlled trial
-
Katsumata N, Yasuda M, Takahashi F, et al. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet. 2009;374(9698):1331-1338.
-
(2009)
Lancet
, vol.374
, Issue.9698
, pp. 1331-1338
-
-
Katsumata, N.1
Yasuda, M.2
Takahashi, F.3
-
25
-
-
84870317593
-
Long-term follow-up of a randomized trial comparing conventional paclitaxel and carboplatin with dose-dense weekly paclitaxel and carboplatin in women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: JGOG 3016 trial
-
Abstr 5003
-
Katsumata N, Yasuda M, Isonishi S, et al. Long-term follow-up of a randomized trial comparing conventional paclitaxel and carboplatin with dose-dense weekly paclitaxel and carboplatin in women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: JGOG 3016 trial. J Clin Oncol. 2012;30 Suppl:Abstr 5003.
-
(2012)
J Clin Oncol
, vol.30
, Issue.SUPPL.
-
-
Katsumata, N.1
Yasuda, M.2
Isonishi, S.3
-
26
-
-
0030986626
-
Weekly cisplatin given for 2months versus cisplatin plus cyclophosphamide given for 5months after cytoreductive surgery for advanced ovarian cancer
-
Bolis G, Favalli G, Danese S, et al. Weekly cisplatin given for 2months versus cisplatin plus cyclophosphamide given for 5months after cytoreductive surgery for advanced ovarian cancer. J Clin Oncol. 1997;15(5):1938-1944.
-
(1997)
J Clin Oncol
, vol.15
, Issue.5
, pp. 1938-1944
-
-
Bolis, G.1
Favalli, G.2
Danese, S.3
-
27
-
-
0033509257
-
Mature results of a prospective randomized trial comparing a three-weekly with an accelerated weekly schedule of cisplatin in advanced ovarian carcinoma
-
Cocconi G, Bella M, Lottici R, et al. Mature results of a prospective randomized trial comparing a three-weekly with an accelerated weekly schedule of cisplatin in advanced ovarian carcinoma. Am J Clin Oncol. 1999;22(6):559-567.
-
(1999)
Am J Clin Oncol
, vol.22
, Issue.6
, pp. 559-567
-
-
Cocconi, G.1
Bella, M.2
Lottici, R.3
-
28
-
-
79951909015
-
Randomized phase III clinical trial evaluating weekly cisplatin for advanced epithelial ovarian cancer
-
Fruscio R, Garbi A, Parma G, et al. Randomized phase III clinical trial evaluating weekly cisplatin for advanced epithelial ovarian cancer. J Natl Cancer Inst. 2011;103(4):347-351.
-
(2011)
J Natl Cancer Inst
, vol.103
, Issue.4
, pp. 347-351
-
-
Fruscio, R.1
Garbi, A.2
Parma, G.3
-
29
-
-
79957720845
-
Single nucleotide polypmorphisms in ERCC1 are associated with disease progression, and survival in patients with advanced stage ovarian and primary peritoneal carcinoma; a Gynecologic Oncology Group study
-
Krivak TC, Darcy KM, Tian C, et al. Single nucleotide polypmorphisms in ERCC1 are associated with disease progression, and survival in patients with advanced stage ovarian and primary peritoneal carcinoma; a Gynecologic Oncology Group study. Gynecol Oncol. 2011;122(1):121-126.
-
(2011)
Gynecol Oncol
, vol.122
, Issue.1
, pp. 121-126
-
-
Krivak, T.C.1
Darcy, K.M.2
Tian, C.3
-
30
-
-
77951438750
-
Population differences in platinum toxicity as a means to identify novel genetic susceptibility variants
-
O'Donnell PH, Gamazon E, Zhang W, et al. Population differences in platinum toxicity as a means to identify novel genetic susceptibility variants. Pharmacogenet Genomics. 2010;20(5):327-337.
-
(2010)
Pharmacogenet Genomics
, vol.20
, Issue.5
, pp. 327-337
-
-
O'Donnell, P.H.1
Gamazon, E.2
Zhang, W.3
-
31
-
-
0034306969
-
Blockade of nuclear factor-kappaB signaling inhibits angiogenesis and tumorigenicity of human ovarian cancer cells by suppressing expression of vascular endothelial growth factor and interleukin 8
-
Huang S, Robinson JB, Deguzman A, Bucana CD, Fidler IJ. Blockade of nuclear factor-kappaB signaling inhibits angiogenesis and tumorigenicity of human ovarian cancer cells by suppressing expression of vascular endothelial growth factor and interleukin 8. Cancer Res. 2000;60(19):5334-5339.
-
(2000)
Cancer Res
, vol.60
, Issue.19
, pp. 5334-5339
-
-
Huang, S.1
Robinson, J.B.2
Deguzman, A.3
Bucana, C.D.4
Fidler, I.J.5
-
32
-
-
36849019301
-
Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: A Gynecologic Oncology Group Study
-
Burger RA, Sill MW, Monk BJ, Greer BE, Sorosky JI. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2007;25(33):5165-5171.
-
(2007)
J Clin Oncol
, vol.25
, Issue.33
, pp. 5165-5171
-
-
Burger, R.A.1
Sill, M.W.2
Monk, B.J.3
Greer, B.E.4
Sorosky, J.I.5
-
33
-
-
36849056497
-
Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer
-
Cannistra SA, Matulonis UA, Penson RT, et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol. 2007;25(33):5180-5186.
-
(2007)
J Clin Oncol
, vol.25
, Issue.33
, pp. 5180-5186
-
-
Cannistra, S.A.1
Matulonis, U.A.2
Penson, R.T.3
-
34
-
-
84855466019
-
A phase 3 trial of bevacizumab in ovarian cancer
-
Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365(26):2484-2496.
-
(2011)
N Engl J Med
, vol.365
, Issue.26
, pp. 2484-2496
-
-
Perren, T.J.1
Swart, A.M.2
Pfisterer, J.3
-
35
-
-
84855425106
-
Incorporation of bevacizumab in the primary treatment of ovarian cancer
-
Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365(26):2473-2483.
-
(2011)
N Engl J Med
, vol.365
, Issue.26
, pp. 2473-2483
-
-
Burger, R.A.1
Brady, M.F.2
Bookman, M.A.3
-
36
-
-
80051913984
-
2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: Report from the Fourth Ovarian Cancer Consensus Conference
-
Stuart GC, Kitchener H, Bacon M, et al. 2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference. Int J Gynecol Cancer. 2011;21(4):750-755.
-
(2011)
Int J Gynecol Cancer
, vol.21
, Issue.4
, pp. 750-755
-
-
Stuart, G.C.1
Kitchener, H.2
Bacon, M.3
-
37
-
-
33947311852
-
What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer?
-
Han ES, Monk BJ. What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer? Gynecol Oncol. 2007;105(1):3-6.
-
(2007)
Gynecol Oncol
, vol.105
, Issue.1
, pp. 3-6
-
-
Han, E.S.1
Monk, B.J.2
-
38
-
-
84861736119
-
OCEANS: A randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer
-
Aghajanian C, Blank SV, Goff BA, et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol. 2012;30(17):2039-2045.
-
(2012)
J Clin Oncol
, vol.30
, Issue.17
, pp. 2039-2045
-
-
Aghajanian, C.1
Blank, S.V.2
Goff, B.A.3
-
39
-
-
77956649079
-
A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer
-
Friedlander M, Hancock KC, Rischin D, et al. A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer. Gynecol Oncol. 2010;119(1):32-37.
-
(2010)
Gynecol Oncol
, vol.119
, Issue.1
, pp. 32-37
-
-
Friedlander, M.1
Hancock, K.C.2
Rischin, D.3
-
40
-
-
80053561888
-
Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer
-
Ledermann JA, Hackshaw A, Kaye S, et al. Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer. J Clin Oncol. 2011;29(28):3798-3804.
-
(2011)
J Clin Oncol
, vol.29
, Issue.28
, pp. 3798-3804
-
-
Ledermann, J.A.1
Hackshaw, A.2
Kaye, S.3
-
41
-
-
84863012011
-
Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer
-
Karlan BY, Oza AM, Richardson GE, et al. Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer. J Clin Oncol. 2012;30(4):362-371.
-
(2012)
J Clin Oncol
, vol.30
, Issue.4
, pp. 362-371
-
-
Karlan, B.Y.1
Oza, A.M.2
Richardson, G.E.3
-
42
-
-
1842509871
-
Mucinous epithelial ovarian cancer: A separate entity requiring specific treatment
-
Hess V, A'Hern R, Nasiri N, et al. Mucinous epithelial ovarian cancer: a separate entity requiring specific treatment. J Clin Oncol. 2004;22(6):1040-1044.
-
(2004)
J Clin Oncol
, vol.22
, Issue.6
, pp. 1040-1044
-
-
Hess, V.1
A'Hern, R.2
Nasiri, N.3
-
43
-
-
80051548022
-
Prognosis of ovarian clear cell carcinoma compared to other histological subtypes: A meta-analysis
-
Lee YY, Kim TJ, Kim MJ, et al. Prognosis of ovarian clear cell carcinoma compared to other histological subtypes: a meta-analysis. Gynecol Oncol. 2011;122(3):541-547.
-
(2011)
Gynecol Oncol
, vol.122
, Issue.3
, pp. 541-547
-
-
Lee, Y.Y.1
Kim, T.J.2
Kim, M.J.3
-
44
-
-
77956813137
-
Prognostic relevance of uncommon ovarian histology in women with stage III/IV epithelial ovarian cancer
-
Mackay HJ, Brady MF, Oza AM, et al. Prognostic relevance of uncommon ovarian histology in women with stage III/IV epithelial ovarian cancer. Int J Gynecol Cancer. 2010;20(6):945-952.
-
(2010)
Int J Gynecol Cancer
, vol.20
, Issue.6
, pp. 945-952
-
-
McKay, H.J.1
Brady, M.F.2
Oza, A.M.3
-
45
-
-
79959838081
-
Integrated genomic analyses of ovarian carcinoma
-
Cancer Genome Atlas Research Network
-
Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474(7353):609-615.
-
(2011)
Nature
, vol.474
, Issue.7353
, pp. 609-615
-
-
-
46
-
-
77956400006
-
Increased incidence of visceral metastases in scottish patients with BRCA1/2-defective ovarian cancer: An extension of the ovarian BRCAness phenotype
-
Gourley C, Michie CO, Roxburgh P, et al. Increased incidence of visceral metastases in scottish patients with BRCA1/2-defective ovarian cancer: an extension of the ovarian BRCAness phenotype. J Clin Oncol. 2010;28(15):2505-2511.
-
(2010)
J Clin Oncol
, vol.28
, Issue.15
, pp. 2505-2511
-
-
Gourley, C.1
Michie, C.O.2
Roxburgh, P.3
-
47
-
-
57149093237
-
"BRCAness" syndrome in ovarian cancer: A case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations
-
Tan DS, Rothermundt C, Thomas K, et al. "BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations. J Clin Oncol. 2008;26(34):5530-5536.
-
(2008)
J Clin Oncol
, vol.26
, Issue.34
, pp. 5530-5536
-
-
Tan, D.S.1
Rothermundt, C.2
Thomas, K.3
-
48
-
-
84856158117
-
Association between BRCA1 and BRCA2mutations and survival in women with invasive epithelial ovarian cancer
-
Bolton KL, Chenevix-Trench G, Goh C, et al. Association between BRCA1 and BRCA2mutations and survival in women with invasive epithelial ovarian cancer. JAMA. 2012;307(4):382-390.
-
(2012)
JAMA
, vol.307
, Issue.4
, pp. 382-390
-
-
Bolton, K.L.1
Chenevix-Trench, G.2
Goh, C.3
-
49
-
-
77956262516
-
Making the best of PARP inhibitors in ovarian cancer
-
Banerjee S, Kaye SB, Ashworth A. Making the best of PARP inhibitors in ovarian cancer. Nat Rev Clin Oncol. 2010;7(9):508-519.
-
(2010)
Nat Rev Clin Oncol
, vol.7
, Issue.9
, pp. 508-519
-
-
Banerjee, S.1
Kaye, S.B.2
Ashworth, A.3
-
50
-
-
84859523588
-
Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer
-
Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med. 2012;366(15):1382-1392.
-
(2012)
N Engl J Med
, vol.366
, Issue.15
, pp. 1382-1392
-
-
Ledermann, J.1
Harter, P.2
Gourley, C.3
|